Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. VERU
VERU logo

VERU Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Veru Inc (VERU) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
2.430
1 Day change
-0.41%
52 Week Range
7.400
Analysis Updated At
2026/04/17
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Veru Inc (VERU) is not a strong buy for a beginner investor with a long-term focus at this time. The stock lacks significant positive catalysts, financial performance is weak, and there are no clear trading signals or strong upward trends. Holding off on investment would be prudent.

Technical Analysis

The MACD is positive and expanding, indicating a mild bullish trend. However, RSI is neutral at 64.706, and moving averages are converging, showing no strong directional momentum. The pre-market price is down 2.43%, trading near the pivot level of 2.411, suggesting limited upside potential in the short term.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

The low open interest put-call ratio indicates a bullish sentiment, but the high option volume put-call ratio suggests bearish short-term sentiment among traders.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
8
Buy
5

Positive Catalysts

  • NULL identified. No news or significant insider or hedge fund activity. MACD is slightly bullish.

Neutral/Negative Catalysts

  • Pre-market price is down 2.43%. Financial performance is weak with declining net income and EPS. No recent news or events to drive upward momentum.

Financial Performance

In Q1 2026, revenue growth was stagnant at 0%, net income dropped by 40.39% YoY to -$5.33M, and EPS declined by 57.38% YoY to -0.26. Gross margin remained at 0%, showing no improvement.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target changes available.

Wall Street analysts forecast VERU stock price to rise
1 Analyst Rating
Wall Street analysts forecast VERU stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.440
sliders
Low
25
Averages
25
High
25
Current: 2.440
sliders
Low
25
Averages
25
High
25
Canaccord
NULL -> Buy
initiated
$25
AI Analysis
2025-12-18
Reason
Canaccord
Price Target
$25
AI Analysis
2025-12-18
initiated
NULL -> Buy
Reason
Canaccord initiated coverage of Veru with a Buy rating and $25 price target. Veru is positioned as a differentiated biotech in obesity drug development, with lead candidate enobosarm, an oral selective androgen receptor agonist, being evaluated in Phase IIb alongside a GLP-1 receptor agonist to preserve muscle during weight loss, the analyst tells investors in a research note. A second Phase IIb trial is planned for 1Q26, with top-line data expected in 1H28, the firm says.

People Also Watch